Cardiometabolic risk factors efficacy of semaglutide in the STEP program.

Amaro, Anastassia; Skolnik, Neil S; Sugimoto, Danny

Amaro, Anastassia; Skolnik, Neil S; Sugimoto, Danny.

Affiliation

Amaro A; Penn Metabolic Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Skolnik NS; Abington Family Medicine, Abington Jefferson Health, Jenkintown, PA, USA.
Sugimoto D; Cedar Crosse Research Center, Chicago, IL, USA.

Postgrad Med ; 134(sup1): 18-27, 2022 Jan.

Article in En | MEDLINE | ID: mdl-36691308

Subject(s)

Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Cardiometabolic Risk Factors; Cardiovascular Diseases/drug therapy; Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptides; Hypoglycemic Agents/therapeutic use; Lipids; Obesity/drug therapy; Overweight; Weight Loss

Key words

Semaglutide 2.4 mg; anti-obesity medication; cardiometabolic parameters; obesity; overweight; weight loss

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Postgrad Med Year: 2022 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google